
Michael Khoo
Articles
-
1 week ago |
ajp.com.au | Jay Cutler |Paul Sapardanis |Henry Briskin |Michael Khoo
“From systemic erasure in medical education to outright discrimination in our care settings” – LGBTQIA+ patients face a lot of barriers to care and medicines access, says one pharmacist advocating in this space “LGBTQIA patients often face fear of judgement, misgendering or having to show up in discomfort when they have to educate their ownThis content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.
-
1 month ago |
ajp.com.au | Bob Tran |Kay Dunkley |Michael Khoo |Megan Haggan
Many Australians struggle with feeling lonely – and the most affected cohort may not be who you think, says one expert AJP Podcast host Carlene McMaugh spoke to Jenny Kirschner, founder of Pharmacy Addressing Loneliness and Social Isolation, to talk about her own experiences with loneliness, the factors which influence it, and what pharmacists canThis content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.
-
1 month ago |
ajp.com.au | Kate Cowling |Bob Tran |Kay Dunkley |Michael Khoo
Pharmacists on the minimum wage are set to get a 14% pay bump after a Fair Work Commission probe found workers in several female-dominated professions and industries have been undervalued An expert panel has determined pharmacists covered by the Pharmacy Industry Award 2020 will receive the total 14.1% pay increase over three years, beginning June 2025. This content is restricted to registered users only.
-
1 month ago |
ajp.com.au | Kate Cowling |Bob Tran |Kay Dunkley |Michael Khoo
US pharmaceutical company Eli Lilly has said it may pull clinical trial funding from Australia if PBS wait times aren’t reduced The drug giant’s head of international operations said Ilya Yuffa told the Australian Financial Review he hasn’t seen much progress on pharmaceutical benefits scheme (PBS) in his three-and-a-half-years in his role. Eli Lilly saidThis content is restricted to registered users only.
-
1 month ago |
ajp.com.au | Bob Tran |Kay Dunkley |Michael Khoo |Megan Haggan
Some of the recent changes to the medicines landscape, with new products, indications and contraindications New Products Momelotinib (as dihydrochloride monohydrate) (Omjjara) and its major circulating metabolite (M21) are inhibitors of wild type Janus Kinase 1 and 2 (JAK1/JAK2) and mutant JAK2V617F, which contribute to signalling of a number of cytokines and growth factors thatThis content is restricted to registered users only.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →